Similar to the ASH abstracts, each year the American Society for
Haematologists publishes a
series of articles that give an in-depth discussion of subjects of
particular importance.
To access each item simply
click on the book beside it.
2011
|
Allogeneic Immunotherapy to Optimize the Graft-versus-Tumor Effect:
Concepts and Controversies |
 |
|
B Cells Behaving Badly: A Better Basis to Behold Belligerence in
B-Cell Lymphomas |
|
|
Tricky and Terrible T-Cell Tumors: These are Thrilling Times for
Testing: Molecular Pathology of Peripheral T-Cell Lymphomas |
|
|
Relapsed/Refractory Diffuse Large B-Cell Lymphoma |
|
|
Therapies for Peripheral T-Cell Lymphomas |
|
2010
|
Long-Term Physiological Side Effects After Allogeneic Bone Marrow
Transplantation |
|
|
Comorbidities and Hematopoietic Cell Transplantation Outcomes |
|
|
Health-Related Quality of Life Following Allogeneic Hematopoietic
Stem Cell Transplantation |
|
|
Host Factors for Risk and Survival in Lymphoma |
|
|
Novel Agents for Follicular Lymphoma |
|
|
2009 |
The 2008 WHO classification of lymphomas: implications for clinical
practice and translational research |
|
|
The incidence, natural history, biology, and treatment of
transformed lymphomas |
|
|
Current treatment standards and emerging strategies in mantle cell
lymphoma |
|
2008
|
Marginal Zone Lymphomas: Management of Nodal, Splenic, and MALT NHL |
|
|
Primary Mediastinal B-Cell Lymphoma |
|
|
Burkitt Lymphoma in Adults |
|
|
Novel Therapies and Role of Transplant in the Treatment of
Peripheral T-Cell Lymphomas |
|
|
Prognosis and Primary Therapy in Peripheral T-Cell Lymphomas |
|
|
Pathobiology and Molecular Profiling of Peripheral T-Cell Lymphomas |
|
|
Recognizing and Managing Chronic Graft-Versus-Host Disease |
|
|
Old and New Cancers after Hematopoietic-Cell Transplantation |
|
|
Does High-Dose Therapy and Autologous Hematopoietic Stem Cell
Transplantation Have a Role in the Primary Treatment of Peripheral
T-Cell Lymphomas? |
|
2007
|
Reduced-Intensity Stem Cell Transplantation "...whereof a little
More than a little is by much too much." |
|
|
GVHD—The Nuts and
Bolts |
|
|
Clinical Features,
Prognosis and Treatment of Follicular Lymphoma |
|
|
Follicular NHL: From
Antibodies and Vaccines to Graft-versus-Lymphoma Effects |
|
|
Monoclonal Antibodies
for B-Cell Lymphomas: Rituximab and Beyond |
|
|
Vaccine Therapy for
B-Cell Lymphomas: Next-Generation Strategies |
|
|
Antibody Therapy in
Aggressive Lymphomas |
|
|
Diagnosis and
Treatment of Childhood Non-Hodgkin Lymphoma |
|
|
Should Adolescents
with NHL Be Treated as Old Children or Young Adults? |
|
2006
|
Controversies in Follicular
Lymphoma: "Who, What, When, Where, and Why?" (Not Necessarily in
That Order!) |
|
|
An Update on Therapy of Primary
Central Nervous System Lymphoma |
|
|
Optimal Use of Prognostic Factors
in Non-Hodgkin Lymphoma |
|
|
Pathobiology of Peripheral T-cell
Lymphomas |
|
|
Primary Cutaneous T-Cell Lymphomas |
|
|
Therapy of Peripheral T/NK
Neoplasms |
|
2005
|
Diffuse Large B-Cell
Lymphoma: Risk Stratification and Management of Relapsed Disease
|
|
|
Aggressive Peripheral
T-Cell Lymphomas (Specified and Unspecified Types) |
|
|
Biology and Treatment
of Epstein-Barr Virus-Associated Non-Hodgkin Lymphomas |
|
|
Clinical Presentation
and Management of Marginal Zone Lymphomas |
|
|
Biology and Management
of Histologic Transformation of Indolent Lymphoma |
|
|
Targeting CD20 in
Follicular NHL: Novel Anti-CD20 Therapies, Antibody Engineering, and
the Use of Radioimmunoconjugates |
|
|
Unique Toxicities and
Resistance Mechanisms Associated with Monoclonal Antibody Therapy |
|
|
Reduced-Intensity
Conditioning Regimens for Hematologic Malignancies: What Have We
Learned over the Last 10 Years? |
|
|
Hematopathology
Approaches to Diagnosis and Prognosis of Indolent B-Cell Lymphomas |
|
